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Background. Patients with unilateral atresia and microtia encounter problems in sound localization and speech understanding
in noise. Although there are four implantable hearing devices available, there is little discussion and evidence on the application
of these devices on patients with unilateral atresia and microtia problems. Objective. This paper will review the details of these
four implantable hearing devices for the treatment of unilateral atresia. They are percuteaneous osseointegrated bone anchored
hearing aid, Vibrant Soundbridge middle ear implant, Bonebridge bone conduction system, and Carina fully implantable hearing
device. Methods. Four implantable hearing devices were reviewed and compared. The clinical decision process that led to the
recommendation of a device was illustrated by using a case study. Conclusions. The selection of appropriate implantable hearing
devices should be based on various factors, including radiological findings and patient preferences, possible surgical complications,
whether the device is Food and Drug Administration- (FDA-)/CE-approved, and the finances. To ensure the accurate evaluation
of candidacy and outcomes, the evaluation methods should be adapted to suite the type of hearing device.
1. Introduction
Difficulties in sound localization and speech understanding
in noise have been underestimated in adults with unilateral
atresia [1].The amplification options for atretic canal patients
are limited; this is because conventional amplification is not a
treatment option due to the absence of an external ear canal.
In addition, the cosmetic concerns of a conventional bone
conduction hearing aid often lead to a relatively low com-
pliance rate. Implantable hearing aids have been developed
recently as alternative treatment options to fill in these gaps.
There are four commercially available implantable hear-
ing devices available as rehabilitative options for patients with
unilateral microtia and atresia. They are
(a) Percutaneous osseointegrated bone anchored hearing
aid (p-BAHA), for example, Cochlear BAHA by
Cochlear Bone Anchored Solutions AB and Ponto by
Oticon Medical AB, Sweden;
(b) Vibrant Soundbridge (VSB) middle ear implant sys-
tem (MED-EL, Innsbruck, Austria);
(c) BoneBridge bone (BB) conduction system (MED-EL,
Innsbruck, Austria);
(d) Otologics MET Carina fully implantable hearing
device (FIHA) (Otologics LLC, Boulder, CO, USA).
All of these devices need to be implanted surgically.These
devices are expected to benefit patients with moderate to
severe hearing, regardless of their type of hearing loss, that is,
sensorineural, conductive, or mixed. However, these devices
differ in terms of the sound transmission pathway, and some,
such as the FIHA, are suitable for adults only.
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1.1. The Percutaneous Bone Anchored Hearing System (p-
BAHA). The bone anchored hearing aid (BAHA) was first
introduced in 1977 as an alternative hearing rehabilitation
option for patients with conductive hearing loss. Later devel-
opments expanded the indications to include single-sided
deafness and mixed hearing loss. The BAHA hearing system
incorporated the concept of osseointegration discovered
by Professor Bra˚nemark, enabling improved comfort and
fine sound quality. It represented a major milestone in the
evolution of bone conduction hearing amplification [2]. Two
commercially available systems of the BAHA hearing devices
include the Cochlear BAHA by Cochlear Bone Anchored
Solutions AB or the Ponto by Oticon Medical AB, Sweden.
These devices are FDA-approved for children of the age of 5
and above; for younger children, a BAHA soft band will be
applied.
The surgical procedure for the BAHA is relatively simple
in comparison with other implantable devices. BAHA is
placed in the mastoid bone. Local anesthesia could be used
for the majority of the adult cases. The most obvious benefit
for the BAHA system is its surgical simplicity; it bypasses
the outer and middle ear pathology and stimulates the inner
ear effectively via direct bone conduction, which is partic-
ularly well suited for patients with aural atresia. However,
despite years of technological advancement, the problem of
postoperative periabutment wound infection has remained
at approximately 5%, which results in a significant negative
impact on the clinical application.
1.2. The Vibrant Soundbridge Middle Ear Implant. An alter-
native to p-BAHA is the Vibrant Soundbridge middle
ear implant system (VSB) (Med-El, Innsbruck, Austria).
The Vibrant Soundbridge (VSB) is a direct-drive, partly
implantable middle ear hearing device which was approved
by the FDA in 2000. It is intended for patients of the age
of 3 and above with a mild to severe degree of hearing loss,
with their bone conduction thresholds at or not worse than
65 dBHL across frequencies.
The VSB system is comprised of two parts, namely, an
internal component of the VSB called the Vibrating Ossicular
Prosthesis (VORP) and an external audio processor (AP).
The VORP consists of an internal coil, a magnet to hold
the Amade´ audio processor over the implant, a demodulator,
the conductor link, and the floating mass transducer (FMT).
The VORP is implanted by a surgical procedure in which
the FMT is attached to a vibratory structure in the middle
ear either via a round window approach (round window
vibroplasty (RWV)) or via ossicular chain coupling [3].
Intraoperative electrocochleography is needed to locate the
best orientation of the floating mass transducer. The details
of the electrocochleography procedure are available in the
guidelines written by Radeloff and colleagues [4]. The AP
is about 1.2 inches in diameter and contains a microphone,
which picks up sounds and converts them into electrical
signals that can be transmitted across the skin to be received
by the implanted internal receiver of the VSB.
Benefits from theVSBdevice include, firstly, the provision
of a unilateral stimulation to the atretic ear, which is beneficial
for those with unilateral hearing loss. Secondly, there is no
pin tract problem as in BAHA. In addition, the patient’s
satisfaction with the sound quality and the improvement
in speech intelligibility are higher and could be sustained
even after five to eight years of implant use [5, 6]. However,
because the VSB surgery involves the manipulation of the
fragile ossicle bones, there are therefore possible risks of sur-
gical trauma and irreparable sensorineural deafness. Other
potential complications include postsurgical displacement
of the implant due to development of scar tissues, taste
disturbance, or damage to the chorda tympani nerve [5–7].
Lastly, magnetic resonance imaging (MRI) is contraindicated
in patients with VSB device.
1.3. The Bonebridge Bone Conduction Implant. The Bone-
bridge (BB) (Med-EL; Innsbruck, Austria) is another feasible
option for children at age of 5 years and above who have
conductive, mixed hearing loss or single-sided deafness with
bone conduction thresholds at 45 dBHL or better at 0.5, 1, 2,
and 3 kHz. It is a semi-implantable bone conduction implant
hearing device consisting of an external audio processor (AP)
worn behind the ear and a bone conduction implant (BCI)
positioned surgically under the skin. The acoustic signals
are recorded by the microphones of the AP, which converts
sounds into electrical signals, and these are then transferred
to the BCI. The BCI then converts the electrical signals to
mechanical vibrations on themastoid bone and thus the inner
ear is stimulated via bone conduction.
Several advantages have been noted with the BB. Firstly,
the BB offers a bilateral stimulation that is similar to the
BAHA.Thus, it is especially beneficial for those with bilateral
hearing loss in that they will need to wear only one device to
achieve desirable outcomes. Secondly, theBBdoes not require
a good middle ear structure for the coupling of the device;
thus it is suitable for patients withmiddle ear pathologies and
who are not feasible for VSB implantation. Thirdly, the risks
associated with the use of MRI are reduced, compared to the
VSB. The BB allows MRI to be done up to 1.5 Tesla.
Although the BB seems to be a better device in terms of
surgical complications and the application ofMRI, compared
to the VSB, the BB system is still pending FDA approval
in the United States’ market. Thus, the BB system may
not be considered as a reimbursable item by a third party
(e.g., healthcare insurance). Other disadvantages of the BB
include possible postsurgical displacement of the BCI and
extrusion of the implant, although this is uncommon. Lastly,
the BB provides bilateral stimulation and thus may not be
desirable when hearing in the other ear is normal; this is
because there is a possible risk of signal interference to the
normal contralateral ear. Careful assessment of individual
preferences and preoperative trial on potential candidates
with the Apollen bone conduction hearing aid provided by
MED-EL could be helpful to determine its suitability before
surgery is performed.
1.4.The Carina Fully Implantable Hearing Aid (Carina FIHA).
The Carina implantable hearing aid, developed by Otologics
LLC (Boulder, CO, USA), was initially developed as a semi-
implantable middle ear transducer (MET) but is now a fully
implantable hearing device. The Carina device consists of
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the implant, the programming system, the charger, and the
remote control. The implant itself contains the electronics
which contain themicrophone, battery, magnet, digital signal
processor, and connector. The system utilizes a microphone
located beneath the skin that picks up acoustic signals, which
are then amplified and converted into an electrical signal.
The signal is sent down the lead and into the transducer and
the ossicular stimulator is coupled directly with the ossicular
chain or the round window [8].
The Carina is considered to be another viable option for
adults with moderate to severe hearing loss of conductive,
sensorineural, or mixed etiologies. The device is CE-marked
for sale and currently is still in the clinical trial stage, and
therefore it has not been cleared for marketing by the FDA
in United States. Three advantages of the Carina device
include the following: (1) among the four devices discussed
in this paper, the Carina is cosmetically the most appealing
because no external processor can be seen; (2) it is easy to
use; and (3) unilateral stimulation is provided. This device
is thus suitable for adults with unilateral hearing loss such
as unilateral congenital atresia. Siegert et al. investigated
the surgical and audiological outcomes of Carina FIHA on
five adults with either unilateral or bilateral congenital aural
atresia [8]. All patients indicated no intra- or postoperative
complications. Audiologically, all five patients demonstrated
an average improvement of aided soundfield thresholds of
approximately 35 dBHLwith the Carina device.This provides
the conclusion that the Carina device offers a new option for
patients with congenital atresia [9].
However, there are several drawbacks of using the Carina
device as follows: (1) it is not suitable for children and
teenagers under 18 years of age; (2) the surgery is difficult
to perform and it requires general anesthesia for about three
hours; (3) revision surgery is required for battery change and
future upgrade; (4) it is MRI-incompatible; (5) it is the most
costly of all the MEIs; and (6) postoperative deterioration
in hearing thresholds has been reported. Local experience
in Hong Kong, with the application of the Carina device
on five adults with sensorineural hearing loss, indicates a
general drop of pure tone air conduction thresholds in all
subjects postoperatively, at an average of 9 dB across the 250–
8,000Hz frequencies. A few cases also indicated a drop in
bone conduction thresholds of about 10–15 dBHL [9]. Thus,
preoperative counseling of the pros and cons of using aCarina
device is suggested [9].
2. Candidacy
A candidate who has unilateral atresia must meet various
criteria in order to be considered for implantation. In general,
three types of considerations should be given: (1) the nature of
the hearing loss, (2) patient preferences, and (3) issues related
to practical usage.
In terms of the nature of the hearing loss, the patient
should be selected according to the following criteria (see
Figure 1 for the clinical decision making process).
(a) The air conduction hearing thresholds must fall
within the manufacturer’s suggested criteria, that is,
not more than a moderate to severe degree of hearing
loss, except for the FIHA, where bone conduction
thresholds are used as one of the selection criteria.
While the BAHA and the BBwould allow hearing loss
up to 45 to 55 dBHL, the VSB and the Carina would
fit a hearing loss of up to 70 to 80 dBHL.
(b) The bone conduction threshold should be stable.
(c) Whether the middle ear structure would allow the
coupling of the transducer.
(d) There should be an absence of retrocochlear pathol-
ogy and auditory processing disorders.
(e) The unaided speech intelligibility should be better
than 50% to 60%. However, there is no speech
discrimination requirement for the BB device.
In regard to patient preferences, patient should under-
stand the following factors (see Figure 1).
(a) The device is only for those who have do not receive
satisfactory benefit from conventional bone conduc-
tion hearing aids or there is a cosmetic concern.
(b) There is limited evidence available for some of these
devices.
(c) Only the BAHA and Carina are FDA- and/or CE-
approved for conductive hearing loss and are eligible
for reimbursement by third parties. Otherwise, the
patient should be willing to pay for the device (i.e.,
VSB and BB).
(d) While local anesthesia is used for implanting the
BAHA, general anesthesia surgical procedures are
recommended for other devices and there are risks
associated with the surgery.
(e) At the moment, the fact is only the BAHA and BB is
MRI conditional, BB can have MRI up to 1.5 Tesla,
while as long as the Baha sound processor is removed
for theMRI procedure, a patient can haveMRI up to 3
Tesla.The use of MRI is contraindicated with the VSB
and Carina.The patient should understand that there
could be issues with MRI assessment in the future.
In regard to the usage of implantable devices, the patient
should be informed about the following.
(a) Due to normal hearing in the good ear, the benefits
from amplification may be limited (e.g., amount of
functional gain, speech intelligibility improvement).
(b) Due to bilateral stimulation by the implant, there
could be a distortion of hearing.
(c) There could be implications related to long-term
reliability of the device and other complications (e.g.,
skin overgrowth, extrusion of device, and device
failure rate).
(d) Cosmetic appearance could be a concern with the
BAHA.
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Age
18 years old and above,
consider:
(1) BAHA or
(2) VSB or
(3) BB or 
(4) FIHA
<5 years old, consider:
(1) headband BAHA or
(2) VSB
>5 years old but less than
18 years old, consider:
(1) BAHA or
(2) VSB
(3) BB
(1) Consider patient’s age
(2) Types of hearing loss
(3) Propose to etiology of hearing loss
Figure 1: Flow chart on the clinical decision making process for implantable hearing devices.
3. Special Considerations in the Evaluation
of an Atretic Ear
The consideration of an appropriate hearing device involves
the examination of hearing thresholds. However, there are
issues in regard to the measurement of air conduction
thresholds in an ear with microtia and atresia because the
calibration of the earphone is based on a normal physiologic
pathway of air conduction. The volume of the ear under a
supra-aural earphone is estimated to be about 6 cm3. How-
ever, this assumption cannot be made in cases of malformed
external ear structures. Difficulties in establishing valid air
conduction thresholds would also mean that we are not
able to establish posttreatment advantages in air conduction
thresholds. Thus, other types of outcome measures, such as
soundfield thresholds measures, should be used.
When evaluating soundfield thresholds, the involvement
of the good contralateral ear should be minimized, in order
to obtain the true thresholds. When speech intelligibility
is measured, the clinician should also consider whether
the objective is to demonstrate the effects of implantation
on hearing in the poor ear only (implant ear) or binaural
hearing. In the former case, the good ear should be plugged
and muffed to prevent its participation so that whether
appropriate amplification has been provided to the poor ear
can be verified. However, if the latter objective is desired,
then the individual should be tested binaurally, without the
good ear being plugged and muffed. Because of the good ear,
it is likely that benefits in speech intelligibility will not be
demonstrated if both speech and noise are being presented
from the front loudspeaker. In other words, the effects of
amplification may not be readily observable unless there is
a spatial separation of speech and noise.
With the other ear having normal hearing, the benefits
from an implant in the atretic ear are expected to beminimal.
Thus, the above objective measures (e.g., soundfield air con-
duction testing and speech intelligibility evaluation) might
not be effective in demonstrating benefits. Self-reports of
aided benefit and satisfaction should be obtained to evaluate
the outcomes.
4. Case Study
Background. K.C. is a 23-year-old man presenting with a
unilateral microtia with congenital complete bony external
Figure 2: The Vibrant Soundbridge (VSB) implantable hearing
device. The VSB system is comprised of two parts: the internal
component is called the vibrating ossicular prosthesis (VORP) and
the external component is an audio processor (AP). The VORP
consists of a receiver coil, a magnet to hold the Amade´ audio
processor over the implant, a demodulator, the conductor link,
and the floating mass transducer (FMT). The receiver coil sends
the sound signal from the audio processor to the demodulator
or electronics package. The demodulator demodulates the signal
so that it can be converted into signals that will drive the FMT.
The conductor link just sends these signals to the FMT. Adapted
frommarketing materials on the VSB, with permission of MED-EL,
Innsbruck, Austria.
auditory canal atresia on the right side, as confirmed by using
a computer tomography (CT) scan. The malleus and incus
had fused together and were found attached to the bony
atretic plate. The stapes, oval window, and round window
appeared normal on a CT scan. His major complaints were
poor sound localization and speech understanding difficul-
ties on the right side, especially in the presence of background
noise. The unaided audiogram for K.C. was indicated in
Figure 3.
While both the VSB and Carina would be good choices,
the VSB was chosen because K.C. was worried about possible
future revision surgery in the case of a battery recharge
problem. The VSB was an appropriate option for his right
ear because CT scan findings showed that his stapes, oval
window, and round window were normal and that therefore
VSB could provide a unilateral stimulation to his right ear.
Y.H. was counseled regarding the risks and benefits of the
VSB (Figure 2). The surgery was performed in October 2012.
Surgical Monitoring. The operation was done under general
anesthesia with facial nerve monitoring. The skin incision
and soft tissue handling were such that the patient may need
to undergo plastic reconstruction of the pinna at a later
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Figure 3: Unaided audiogram before surgery.
stage. Mastoidectomywas performed and access to the round
window was achieved by removing atretic plate, malformed
malleus and incus. The round window membrane needed to
be fully exposed and this was performed by careful removal
of bony overhang at the round window niche by a diamond
burr. To ensure that the round windowmembrane will not be
damaged by the FMT, a layer of perichondrium was placed
on the round window membrane. To allow placement of
the FMT in the round window niche, the titanium clip was
removed.The FMTwas carefully orientated and rested on the
round window area. An extra perichondrium was put onto
the FMT body to provide further stability.
Facial nerve monitoring is essential in this surgery for
identifying any abnormal course of facial nerves and for
avoiding facial nerve injury. Compound action potential
(CAP) thresholds were examined during electrocochleogra-
phy (ECochG) intraoperatively to determine the best site of
the FMT placement as well as to evaluate the function of the
implant system. With the electrodes placed on the promon-
tory (active), vertex (reference), and forehead (ground), an
increased CAP amplitude was observed with the FMT, and
the goal was to achieve the best CAP thresholds possible.
Device Fitting. The device was activated eight weeks after
the surgery. This wait was required for wound healing both
internally and externally. Based on the unaided soundfield
hearing thresholds obtained from the implanted ear, the
Amade´ audio processor (MED-EL; Innsbruck, Austria) was
programmed with the Connexx 6.11 software equipped with
the Symfit database Rev.5.0. The default desired sensation
level (DSL I/O) fitting formula was applied. Although the
NAL/NL1 fitting formula is also available, it has not been
modified to yield gain targets appropriate for a direct-drive
device. When the aid was first switched on, the patient was
not able to tolerate the prescribed gain. However, verification
0
10
20
30
40
50
60
70
80
90
100
110
120
Frequency (Hz)
Unaided
Aided with VSB (3 months afer operation)
125 250 500 1k 2k 3k 4k 8k
T
re
sh
ol
ds
 (d
B 
H
L)
Figure 4: Unaided (U) and aided (A) soundfield audiogram
obtained 3 months after the implantation of VSB in the right ear.
Thresholds were measured with the warble tone signals presented
from the poor ear (at 90 degree azimuths).The left (nonimplant) ear
was plugged and muffed during testing.
of the VSB device gain was difficult because the VSB is not an
acoustic device. It is not possible to perform real ear mea-
surements; soundfield aided thresholds, sentence reception
thresholds (SRTs), and self-reports were obtained to evaluate
the outcomes. K.C. returned for a fine-tuning session two
weeks after device activation to ensure that he was listening at
most comfortable levels as well as obtaining benefits from the
device. Informal feedback on sound tolerance was obtained.
Results. Change in residual hearing was evaluated by com-
paring the preoperative unaided bone conduction thresh-
olds to the postoperative bone conduction thresholds. The
results revealed no obvious change at any frequency. Figure 4
presents unaided air and bone conduction thresholds before
the surgery. The hearing thresholds were maintained after
surgery. In addition, there were no postoperative complica-
tions observed or reported by K.C. after surgery.
Verification of the Implantable Hearing Device Performance.
One of K.C.’s chief preimplant complaints was his difficulty
in picking up the signals from the right ear. In order to
assess the aided benefits with the implant, aided soundfield
thresholds were measured with warble tone signals presented
at 90 degree azimuths, with the left ear both plugged and
muffed. With the VSB set at the most comfortable listening
level, it was also shown that VSB offered functional gains
of 5 to 20 dB across the frequencies from 500Hz to 4 kHz,
when compared with the unaided thresholds (Figure 4).
The amount of functional gain was less than that (45.5 dB)
reported by Frenzel et al. [10]. However, the gain could not be
adjusted to a higher volume setting because of intolerance.
Aided thresholds ranged from 35 to 50 dBHL, which is
slightly worse than those reported in the literature [10].
In the current case, we had aimed to present the results
to demonstrate both the effects of amplification on the
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poor ear and binaural hearing. Speech reception thresholds
(SRTs) were measured 3 months after implantation, when
acclimatization, if any, would have been completed. With
the good ear plugged and muffed, the SRT of the poor ear
improved to 50.8 dB (A) in quiet, suggesting that although
the VSB implant improved understanding of moderately soft
speech, the benefit has not been optimized for soft speech.
These results are consistent with findings in aided soundfield
thresholds. SRT was −0.4 dB (A) in noise, thereby suggesting
no improvement from the unaided condition. Thus, the
implant improved the audibility of signals but not the S/N for
50% intelligibility when listening in noise.
With binaural hearing in quiet, there was a slight eleva-
tion of SRT (0.8 to 3.8 dB) when compared to the unaided
conditions (Figure 5). However, any changes smaller than
3.1 dB are within the confidence interval for test and retest
[11], and therefore they could not be regarded as significant
from a statistical point of view.
In noise, as shown in Figure 6, the use of the VSB implant
did not improve binaural squelch in the noise front condition;
that is, the SRT did not improve compared to unaided,
probably because the gain of the implant was low and thus
did not yield true binaural hearing. When the noise was on
the nonimplant side (good ear), the use of an implant-assisted
speech reception (and thus SRT) improved to −2.5 dB S/N.
Compared to when unaided, the patient was better able
to take advantage of the spatial separation of speech and
noise when noise was moved from the front to the implant
side, resulting in an improvement of 6.2 dB in SRT. Overall,
however, the changes in SRTs were small and could not be
regarded as significant.
Self-reported aided benefit and satisfaction were mea-
suredwith the twoChinese versions of the abbreviated profile
of hearing aid benefit (APHAB) and the satisfaction with
amplification in daily life (SADL) [12, 13]. The global score
on the APHAB was 52 (with 100 indicating the greatest
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Figure 6: Speech reception thresholds (SRT) obtained in noise using
the Cantonese version of the Hearing In Noise Test (CHINT). SRTs
were obtained unaided and aided at 3 months after activation of the
VSB.
benefit) and on the SADL it was 4.29 (with 5 indicating
the greatest satisfaction). Y.H. was satisfied with the VSB
middle ear implant in his right ear, although the benefits were
reportedly only moderate. However, these findings are not
unexpected, given that the contralateral ear exhibits normal
hearing ability. The patient also reported good sound quality
and comfort and he accepted the appearance of the aids aswas
often reported in previous studies [10]. Y.H. used the VSB for
approximately 4 to 5 hours per day, primarily for his part-time
work and for communication at home. His ability to hear the
signals from the right ear (the poor ear) reportedly improved
his localization ability, despite the distorted interaural phase
and time differences due to the use of a hearing device in one
ear.
5. Discussion
Overall, there aremany practical concernswhenmaking clin-
ical decisions on the selection of an appropriate implantable
device for an adult with unilateral atresia. One of the most
important questions to ask is the age of the patient (see
Figure 1). The second question will be the types of hearing
loss and thirdly it would be the etiologies of hearing loss.
For microtia patient with pure conductive hearing loss,
the underlying cause is likely due to malformed ossicles;
then the option of VSB surgery should only be considered
after radiological studies where an appropriate coupling is
possible. The options of BAHA and BB do not have this
constraint. However, the clinician should be aware that both
the BAHA and BB provide bilateral stimulations and thus
they may introduce interference to the contralateral ear. In
contrast, the VSB and Carina FIHA provide a unilateral
stimulation of the worse ear. Skin tract problem of BAHA
must be thoroughly discussed. Also the VSB and FIHA
are neither MRI-incompatible nor FDA-approved, and the
potential candidates should be well informed of the risks
including worsening of hearing loss and implant failure
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before they opt for a relatively difficult operating procedure
in VSB and FIHA.
Regarding the cost, the FIHA is the most expensive in
comparison with the VSB and BB. Thus, preoperative coun-
seling of the risks and benefits of each device is important.
6. Conclusion
Despite the lack of high-level evidence about these devices,
the selection of appropriate implantable hearing devices
should be based on various factors, including radiological
findings and patient preferences. In addition, surgical com-
plications, whether the device is FDA-/CE-approved, and the
finances should be considered. To ensure the accurate eval-
uation of candidacy and outcomes, the evaluation methods
should be adapted to suit the type of hearing device.
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